Form 4: Adaptive Biotechnologies CEO Chad Robins Executes Stock Option and Sells Shares Under 10b5-1 Plan

Adaptive Biotechnologies CEO Chad Robins exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Chad Robins, CEO and Chairman of Adaptive Biotechnologies, executed stock options to acquire common stock and subsequently sold a portion of those shares.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 26, 2024.
• On February 19, 2025, Robins exercised options to acquire 186,080 shares at $6.32 per share and sold the same amount at a weighted average price of $8.46, resulting in 2,576,701 shares owned directly.
• On February 20, 2025, Robins exercised options to acquire 99,107 shares at $6.32 per share and sold the same amount at a weighted average price of $8.44, resulting in 2,576,701 shares owned directly.
• The sales prices ranged from $8.30 to $8.67 on February 19 and $8.30 to $8.69 on February 20.
• Following these transactions, Robins continues to beneficially own 2,576,701 shares of Adaptive Biotechnologies Corp.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of a 10b5-1 trading plan allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.

Comparison to Industry Standards

• Insider transactions are common across publicly traded companies, and the use of 10b5-1 plans is a standard practice to ensure compliance with securities laws.
• Comparing the CEO's trading activity to peers at companies like Illumina (ILMN) or Guardant Health (GH) would require analyzing their respective Form 4 filings and understanding their individual compensation structures and trading strategies.
• The reported weighted average sales prices are within a normal range for market fluctuations.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan suggests the sales were planned and not based on sudden changes in the company's outlook.
• Employees may be interested in the CEO's trading activity, but the pre-arranged nature of the plan should alleviate concerns about insider information.

Key Dates

Keywords

Adaptive Biotechnologies, Chad Robins, stock options, Form 4, 10b5-1 trading plan, insider trading, ADPT, share sales